- Leverages Poseida s proprietary allogeneic CAR-T platform to develop innovative convertibleCAR® programs targeting solid tumors -
TOKYO and SAN DIEGO, May 1, 2024 /PRNewswire/ Astellas.
Malin Corp PLC - Dublin-based investor in life sciences companies - Investee company Poseida Therapeutics Inc enters into a research collaboration and licensing agreement with Xyphos Biosciences Inc,.
IN BRIEF: Malin Corp investee signs agreement with Astellas Pharma lse.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lse.co.uk Daily Mail and Mail on Sunday newspapers.
San Francisco-based Xyphos Biosciences Inc. is pooling technology platforms with Boston’s Kelonia Therapeutics Inc. in a novel immuno-oncology (I-O) drug discovery deal that could fetch more than $800 million. Xyphos and Kelonia will collaborate to develop a maximum of two in vivo CAR T-cell therapy programs, utilizing both Kelonia’s in vivo gene placement system called iGPS and Xyphos’ Accel technology platform.
Astellas and Kelonia Therapeutics Enter into Research and License Agreement to Develop Novel Immuno-Oncology Therapeutics streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.